Synairgen plc (SYGGF)

0,0660 0,0000 (0,00%) Börsenschluss: 01:31PM EDT

Synairgen plc

Mailpoint 810
Level F, South Block Southampton General Hospital Tremona Road
Southampton SO16 6YD
United Kingdom
44 23 8051 2800
https://www.synairgen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 34

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Richard Marsden	CEO, MD & Executive Director	410,75k	N/A	1967
Prof. Stephen T. Holgate CBE, M.D.	Co-Founder, Non-Executive Director & Member of Scientific Advisory Board	55,1k	N/A	1947
Dr. Phillip David Monk	Chairman of Scientific Advisory Board, Chief Scientific Officer & Executive Director	300,55k	N/A	1969
Prof. Donna Davies	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Prof. Ratko Djukanovic	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Joseph Tregonning Colliver F.C.A.	CFO & Executive Director	N/A	N/A	1980
Dr. Gareth E. Walters Ph.D.	Chief Regulatory Officer	N/A	N/A	1959
Ms. Jody Brookes	Senior VP & Head of Clinical Operations	N/A	N/A	N/A
Mr. Richard Francis	Senior VP and Head of CMC & Quality	N/A	N/A	N/A
Dr. Victoria Tear	Head of Laboratory	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Corporate Governance

Synairgen plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.